DeepMed Research

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Patients With Advanced Breast Cancer

Phase 1

Terminated

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer
Hormone Receptor-positive Breast Cancer

Interventions: Drug: Part 1
Drug: Part 2
Drug: Part 3

First Posted Date: 2021-06-28

Last Posted Date: 2023-05-22

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 9

Registration Number: NCT04942054

Locations: 🇮🇳
HCG Manavata cancer Centre, Nashik, Maharashtra, India
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇮🇳
Noble Hospital Pvt. Ltd.,, Pune, Maharashtra, India

and more 3 locations

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Withdrawn

Conditions: Locally Recurrent Cancer
Metastatic Breast Cancer

Interventions: Drug: PICS (Reconstitution Method 1 or 2)

First Posted Date: 2020-04-02

Last Posted Date: 2020-06-01

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Registration Number: NCT04332549

Locations: 🇮🇳
SPARC Site 21, Ahmadabad, Gujarat, India
🇮🇳
SPARC Site 13, Bangalore, Karnataka, India
🇮🇳
SPARC Site 17, Nagpur, Maharashtra, India

and more 19 locations

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

Phase 1

Completed

Conditions: Healthy Volunteer Study

Interventions: Drug: matching placebo
Drug: SCO-120

First Posted Date: 2020-01-27

Last Posted Date: 2023-04-21

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 140

Registration Number: NCT04242953

Locations: 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
🇺🇸
BioPharma Services USA Inc., Creve Coeur, Missouri, United States
🇺🇸
AXIS Clinicals, Dilworth, Minnesota, United States

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Phase 2

Terminated

Conditions: Early Parkinson Disease

Interventions: Drug: K0706
Other: placebo

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-18

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 513

Registration Number: NCT03655236

Locations: 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇵🇱
SINGUA Sp. Z o.o., Warszawa, Mazowieckie, Poland
🇵🇱
Neuro-Care - Sp. z o.o. Sp. Komandytowa Ul. Szpitalna 6, Siemianowice Śląskie, Slaskie, Poland

and more 74 locations

To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Hydrocodon bitartrate-acetaminophen arm 1
Drug: Hydrocodon bitartrate-acetaminophen arm 2
Drug: Reference

First Posted Date: 2018-06-26

Last Posted Date: 2019-04-29

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 32

Registration Number: NCT03567941

Locations: 🇨🇦
SPARC Site 1, Toronto, Ontario, Canada

Evaluation of Safety and Efficacy of PDP-716

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Brimonidine Tartrate Ophthalmic Suspension
Drug: Brimonidine Tartrate Ophthalmic Solution

First Posted Date: 2018-03-01

Last Posted Date: 2022-02-15

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 682

Registration Number: NCT03450629

Locations: 🇺🇸
SPARC Site 27, Miami, Florida, United States
🇺🇸
SPARC Site 16, Miami, Florida, United States
🇺🇸
SPARC Site 38, Burbank, California, United States

and more 44 locations

To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K0706

First Posted Date: 2018-02-26

Last Posted Date: 2020-01-14

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 18

Registration Number: NCT03445338

Locations: 🇺🇸
SPARC Site 1, Glendale, California, United States

Evaluation of Efficacy and Safety of SDN-037

Phase 3

Completed

Conditions: Inflammation and Pain Associated With Ocular Surgery

Interventions: Drug: Placebo
Drug: SDN-037

First Posted Date: 2018-02-08

Last Posted Date: 2021-05-17

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 325

Registration Number: NCT03426267

Locations: 🇺🇸
SPARC Site 10, Santa Barbara, California, United States
🇺🇸
SPARC Site 18, Fort Myers, Florida, United States
🇺🇸
SPARC Site 12, Sun City, Arizona, United States

and more 16 locations

Bioavailability Study of K0706 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K0706

First Posted Date: 2017-10-20

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 24

Registration Number: NCT03316820

Locations: 🇺🇸
SPARC Site 1, Las Vegas, Nevada, United States

Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Recurrent or Metastatic Breast Cancer

Interventions: Drug: Reference1613
Drug: SPARC1613

First Posted Date: 2017-04-12

Last Posted Date: 2019-05-03

Lead Sponsor: Sun Pharma Advanced Research Company Limited

Target Recruit Count: 142

Registration Number: NCT03109249

Locations: 🇮🇳
SPARC Site 4, Pune, Maharashtra, India
🇮🇳
SPARC Site 15, Khorda, Orissa, India
🇮🇳
SPARC Site 9, Aurangabad, Marashtra, India

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy